Physician profile
Eric Curfman
NPI 1023694825
$2,688.12
in general payments reported to CMS, 2019-2025
24 companies · $824 in 2025
The $824 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $99.39 · 2023: $603 · 2024: $1,161 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,588.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $591.84 | 2023-2025 | Briviact, Fintepla, Rystiggo |
| Alexion Pharmaceuticals, INC. | $267.91 | 2023-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $247.49 | 2024 | |
| Emd Serono, INC. | $221.67 | 2023-2025 | Mavenclad |
| Sk Life Science, INC. | $175.36 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $170.80 | 2024-2025 | Wainua, Andexxa |
| Lilly USA, LLC | $152.24 | 2024-2025 | Amyvid, Kisunla, Emgality |
| Averitas Pharma INC. | $138.17 | 2023-2024 | Qutenza |
| Jazz Pharmaceuticals INC. | $134.45 | 2023-2024 | Epidiolex |
| Takeda Pharmaceuticals U.S.A., INC. | $130.82 | 2023-2025 | Hyqvia, Gammagard |
| Genentech USA, INC. | $78.13 | 2023-2024 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Tg Therapeutics, INC. | $58.90 | 2023-2025 | |
| Genzyme Corporation | $57.00 | 2022-2023 | |
| Lundbeck LLC | $37.97 | 2025 | Vyepti |
| Amgen INC. | $31.56 | 2025 | Uplizna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $29.78 | 2023 | Botox |
| Pfizer INC. | $28.05 | 2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $27.89 | 2022 | |
| Csl Behring | $24.73 | 2025 | Kcentra, Privigen |
| Teva Pharmaceuticals USA, INC. | $17.99 | 2025 | Austedo Xr |
| Biogen, INC. | $17.37 | 2022 | |
| Amylyx Pharmaceuticals, INC. | $16.90 | 2024 | Relyvrio |
| Horizon Therapeutics Plc | $15.90 | 2022 | |
| Neurelis, INC. | $15.20 | 2025 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Curfman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.